Piper Sandler lowers Arbor Realty Trust stock price target on credit issues
Investing.com - Cantor Fitzgerald has reiterated its Overweight rating on Gossamer Bio Inc. (NASDAQ:GOSS) ahead of the company’s PROSERA clinical trial readout expected in February 2026. According to InvestingPro data, analysts maintain a bullish consensus on GOSS, with price targets ranging from $5 to $15.
The research firm noted improving investor sentiment as the biotech company approaches its key data readout, despite some investors taking profits after the stock’s rise from $0.85 to over $3. This impressive rally has translated into a 243.8% year-to-date return, though InvestingPro analysis indicates the stock is currently in overbought territory.
Cantor Fitzgerald identified varied investor perspectives on GOSS, with some enthusiastic about the current setup while others remain concerned about competitor Aerovate’s influence on the space.
The firm acknowledged near-term risk as some investors may take gains before the binary readout event, which is typical for clinical-stage biotech companies approaching major data announcements.
Cantor Fitzgerald projects potential 75-100%+ upside if the PROSERA trial results are positive, expressing confidence in a favorable outcome from the February 2026 readout.
In other recent news, Gossamer Bio has seen notable activity with analysts revising their ratings and price targets for the company. UBS upgraded Gossamer Bio’s stock rating from Neutral to Buy, increasing the price target from $1.25 to $9.00. This upgrade is linked to the anticipated Phase 3 trial data for Gossamer’s seralutinib treatment for pulmonary arterial hypertension (PAH), expected in February. UBS highlighted an "underappreciated probability of success" for this treatment. Additionally, H.C. Wainwright has reiterated its Buy rating on Gossamer Bio, maintaining a price target of $10.00. This decision follows a literature review of seralutinib, supporting a positive outlook for the drug’s potential. These developments reflect growing optimism among analysts regarding Gossamer Bio’s prospects in the PAH treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.